EGFR and non-small cell lung carcinoma: In a previous phase I study, rezivertinib resulted in an objective response rate (ORR) of 59.3%, a disease control rate (DCR) of 91.3%, and a median progression-free survival (PFS) of 9.7 months for advanced NSCLC patients with EGFR T790M mutation, and the recommended phase II dose (RP2D) was identified as 180 mg once daily [17].